The contribution of methotrexate exposure and host factors on transcriptional variance in human liver

Toxicological Sciences

Volumn 97, Issue 2, 2007, Pages 582-594

  Belinsky, Glenn S ^a   Parke, Ann L ^a   Huang, Qihong ^b   Blanchard, Kerry ^b   Jayadev, Supriya ^b   Stoll, Raymond ^b   Rothe, Marti ^a   Achenie, Luke E K ^c   Gupta, Rishi R ^c   Wu, George Y ^a   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Complement; Fibrosis; Liver; Methotrexate; Rheumatic disease; Steatosis

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C5; LIPID; MESSENGER RNA; METHOTREXATE;

ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EXPOSURE; FATTY LIVER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; LIVER FIBROSIS; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; UNINDEXED SEQUENCE; UPREGULATION;

ADULT; AGED; BIOPSY; CLUSTER ANALYSIS; COMPLEMENT ACTIVATION; FEMALE; FOLIC ACID ANTAGONISTS; GENE EXPRESSION REGULATION; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHEUMATIC DISEASES; RNA;

MUS;

EID: 34447545746     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm067     Document Type: Article

References (62)

1. Ahern, M. J., Kevat, S., Hill, W., Hayball, P. J., Harley, H., and Hall, P. D. (1991). Hepatic methotrexate content and progression of hepatic fibrosis: Preliminary findings. Ann. Rheum. Dis. 50, 477-480.
2. Barzik, M., Kotova, T. I., Higgs, H. N., Hazelwood, L., Hanein, D., Gertler, F. B., and Schafer, D. A. (2005). Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins. J. Biol. Chem. 280, 28653-28662.
3. Baugh, L. R., Hill, A. A., Brown, E. L., and Hunter, C. P. (2001). Quantitative analysis of mRNA amplification by in vitro transcription. Nucleic Acids Res. 29, E29.
4. Beyeler, C., Reichen, J., Thomann, S. R., Lauterburg, B. H., and Gerber, N. J. (1997). Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: A longitudinal study. Br. J. Rheumatol. 36, 338-344.
5. Blanquicett, C., Johnson, M. R., Heslin, M., and Diasio, R. B. (2002). Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: Applications in pharmacogenomic gene expression studies. Anal. Biochem. 303, 209-214.
6. Boffa, M. J., Chalmers, R. J., Haboubi, N. Y., Shomaf, M., and Mitchell, D. M. (1995). Sequential liver biopsies during long-term methotrexate treatment for psoriasis: A reappraisal. Br. J. Dermatol. 133 774-778.
7. Cales, P., Oberti, F., Michalak, S., Hubert-Fouchard, I., Rousselet, M. C., Konate, A., Gallois, Y., Ternisien, C., Chevailler, A., and Lunel, F. (2005). A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42, 1373-1381.
8. Chalmers, R. J., Kirby, B., Smith, A., Burrows, P., Little, R., Horan, M., Hextall, J. M., Smith, C. H., Klaber, M., and Rogers, S. (2005). Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: A multicentre audit and health economic analysis. Br. J. Dermatol. 152, 444-450.
9. Chen, X., Baker, S. M., and Chen, G. (2005). Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J. Appl. Toxicol. 25, 354-360.
10. Comer, K. A., Falany, J. L., and Falany, C. N. (1993). Cloning and expression of human liver dehydroepiandrosterone sulphotransferase. Biochem. J. 289(Pt 1), 233-240.
11. Deighton, C. M., Walker, D. J., Griffiths, I. D., and Roberts, D. F. (1989). The contribution of HLA to rheumatoid arthritis. Clin. Genet. 36, 178-182.
12. Deng, Q. G., She, H., Cheng, J. H., French, S. W., Koop, D. R., Xiong, S., and Tsukamoto, H. (2005). Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42, 905-914.
13. Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M., and Kremer, J. (2004). Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766-2774.
14. Falany, C. N., Comer, K. A., Dooley, T. P., and Glatt, H. (1995). Human dehydroepiandrosterone sulfotransferase. Purification, molecular cloning, and characterization. Ann. NY Acad. Sci. 774, 59-72.
15. Faust, J. R., Rodman, J. S., Daniel, P. F., Dice, J. F., and Bronson, R. T. (1994). Two related proteolipids and dolichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis. J. Biol. Chem. 269, 10150-10155.
16. Fleisch, H., Schibler, D., Maerki, J., and Frossard, I. (1965). Inhibition of aortic calcification by means of pyrophosphate and polyphosphates. Nature 207, 1300-1301.
17. Friedman, S. L. (2004). Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1, 98-105.
18. Gertler, F. B., Niebuhr, K., Reinhard, M., Wehland, J., and Soriano, P. (1996). Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell 87, 227-239.
19. Hall, P. D., Jenner, M. A., and Ahern, M. J. (1991). Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology 14, 906-910.
20. Hillebrandt, S., Wasmuth, H. E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R.,Wilkens, G., Geier, A., Lorenzen, J., et al. (2005). Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 37, 835-843.
21. Ho, A. M., Johnson, M. D., and Kingsley, D. M. (2000). Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289, 265-270.
22. Hughes, L. B., Beasley, T. M., Patel, H., Tiwari, H. K., Morgan, S. L., Baggott, J. E., Saag, K. G., McNicholl, J., Moreland, L. W., Alarcon, G. S., et al. (2006). Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1121-1123.
23. Imbert-Bismut, F., Messous, D., Thibault, V., Myers, R. B., Piton, A., Thabut, D., Devers, L., Hainque, B., Mercadier, A., and Poynard, T. (2004). Intralaboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin. Chem. Lab. Med. 42, 323-333.
24. Jawaheer, D., Seldin, M. F., Amos, C. I., Chen, W. V., Shigeta, R., Etzel, C., Damle, A., Xiao, X., Chen, D., Lum, R. F., et al. (2003). Screening the genome for rheumatoid arthritis susceptibility genes: A replication study and combined analysis of 512 multicase families. Arthritis Rheum. 48, 906-916.
25. John, S., Amos, C., Shephard, N., Chen, W., Butterworth, A., Etzel, C., Jawaheer, D., Seldin, M., Silman, A., Gregersen, P., et al. (2006). Linkage analysis of rheumatoid arthritis in US and UK families reveals interactions between HLA-DRB1 and loci on chromosomes 6q and 16p. Arthritis Rheum. 54, 1482-1490.
26. Kishi, M., Maeyama, S., Koike, J., Aida, Y., Yoshida, H., and Uchikoshi, T. (1996). Correlation between intrasinusoidal neutrophilic infiltration and ceroid-lipofuscinosis in alcoholic liver fibrosis with or without fatty change: Clinicopathological comparison with nutritional fatty liver. Alcohol Clin. Exp. Res. 20, 366A-370A.
27. Kremer, J. M. (2002). Not yet time to change the guidelines for monitoring methotrexate liver toxicity: They have served us well. J. Rheumatol. 29, 1590-1592.
28. Kristensen, D. B., Kawada, N., Imamura, K., Miyamoto, Y., Tateno, C., Seki, S., Kuroki, T., and Yoshizato, K. (2000). Proteome analysis of rat hepatic stellate cells. Hepatology 32, 268-277.
29. Leifeld, L., Dumoulin, F. L., Purr, I., Janberg, K., Trautwein, C., Wolff, M., Manns, M. P., Sauerbruch, T., and Spengler, U. (2003). Early up-regulation of chemokine expression in fulminant hepatic failure. J. Pathol. 199, 335-344.
30. Levy, M. T., McCaughan, G. W., Marinos, G., and Gorrell, M. D. (2002). Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93-101.
31. Lewindon, P. J., Pereira, T. N., Hoskins, A. C., Bridle, K. R.,Williamson, R. M., Shepherd, R. W., and Ramm, G. A. (2002). The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am. J. Pathol. 160, 1705-1715.
32. Li, A., Jiao, X., Munier, F. L., Schorderet, D. F., Yao, W., Iwata, F., Hayakawa, M., Kanai, A., Shy Chen, M., Alan Lewis, R., et al. (2004). Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am. J. Hum. Genet. 74, 817-826.
33. Lonka, L., Aalto, A., Kopra, O., Kuronen, M., Kokaia, Z., Saarma, M., and Lehesjoki, A. E. (2005). The neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated in mouse brain and up-regulated in the hippocampal kindling model of epilepsy. BMC Neurosci. 6, 27.
34. MacGregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J., Aho, K., and Silman, A. J. (2000). Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30-37.
35. Malatjalian, D. A., Ross, J. B.,Williams, C. N., Colwell, S. J., and Eastwood, B. J. (1996). Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can. J. Gastroenterol. 10, 369-375.
36. Maurice, P. D., Maddox, A. J., Green, C. A., Tatnall, F., Schofield, J. K., and Stott, D. J. (2005). Monitoring patients on methotrexate: Hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br. J. Dermatol. 152, 451-458.
37. McKee, S., Pendleton, A., Dixey, J., Doherty, M., and Hughes, A. (2004). Autosomal dominant early childhood seizures associated with chondrocalcinosis and a mutation in the ANKH Gene. Epilepsia 45 1258-1260.
38. Nakatsukasa, H., Nagy, P., Evarts, R. P., Hsia, C. C., Marsden, E., and Thorgeirsson, S. S. (1990). Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J. Clin. Investig. 85 1833-1843.
39. Pawlak, K., Pawlak, D., and Mysliwiec, M. (2004). Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma levels in uraemic patients. Cytokine 28, 197-204.
40. Pendleton, A., Johnson, M. D., Hughes, A., Gurley, K. A., Ho, A. M., Doherty, M., Dixey, J., Gillet, P., Loeuille, D., McGrath, R., et al. (2002). Mutations in ANKH cause chondrocalcinosis. Am. J. Hum. Genet. 71, 933-940.
41. Qin, X., and Gao, B. (2006). The complement system in liver diseases. Cell. Mol. Immunol. 3, 333-340.
42. Rachow, J.W., and Ryan, L. M. (1988). Inorganic pyrophosphate metabolism in arthritis. Rheum. Dis. Clin. North Am. 14, 289-302.
43. Radich, J. P., Mao, M., Stepaniants, S., Biery, M., Castle, J., Ward, T., Schimmack, G., Kobayashi, S., Carleton, M., Lampe, J., et al. (2004). Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 83, 980-988.
44. Richard, S., Guerret, S., Gerard, F., Tebib, J. G., and Vignon, E. (2000). Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: Application of a new semi-quantitative scoring system. Rheumatology (Oxford) 39, 50-54.
45. Rinn, J. L., Rozowsky, J. S., Laurenzi, I. J., Petersen, P. H., Zou, K., Zhong, W., Gerstein, M., and Snyder, M. (2004). Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev. Cell 6, 791-800.
46. Risch, N., and Merikangas, K. (1996). The future of genetic studies of complex human diseases. Science 273, 1516-1517.
47. Roderfeld, M., Weiskirchen, R., Wagner, S., Berres, M. L., Henkel, C., Grotzinger, J., Gressner, A. M., Matern, S., and Roeb, E. (2006). Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. Faseb J. 20, 444-454.
48. Roenigk, H. H., Jr, Auerbach, R., Maibach, H. I., and Weinstein, G. D. (1982). Methotrexate guidelines - Revised. J. Am. Acad. Dermatol. 6, 145-155.
49. Rossi, E., Adams, L., Prins, A., Bulsara, M., de Boer, B., Garas, G., MacQuillan, G., Speers, D., and Jeffrey, G. (2003). Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem. 49, 450-454.
50. Santavuori, P. (1988). Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 10, 80-83.
51. Schuppan, D. (1991). Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J. Hepatol. 13(Suppl. 3), S17-S25.
52. t Hoen, P. A., de Kort, F., van Ommen, G. J., and den Dunnen, J. T. (2003). Fluorescent labelling of cRNA for microarray applications. Nucleic Acids Res. 31, e20.
53. Takahara, T., Kojima, T., Miyabayashi, C., Inoue, K., Sasaki, H., Muragaki, Y., and Ooshima, A. (1988). Collagen production in fat-storing cells after carbon tetrachloride intoxication in the rat. Immunoelectron microscopic observation of type I, type III collagens, and prolyl hydroxylase. Lab. Investig. 59, 509-521.
54. Tsui, F. W., Tsui, H. W., Cheng, E. Y., Stone, M., Payne, U., Reveille, J. D., Shulman, M. J., Paterson, A. D., and Inman, R. D. (2003). Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum. 48, 791-797.
55. Tusher, V. G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98, 5116-5121.
56. Urano, W., Taniguchi, A., Yamanaka, H., Tanaka, E., Nakajima, H., Matsuda, Y., Akama, H., Kitamura, Y., and Kamatani, N. (2002). Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12, 183-190.
57. Weimer, J. M., Kriscenski-Perry, E., Elshatory, Y., and Pearce, D. A. (2002). The neuronal ceroid lipofuscinoses: Mutations in different proteins result in similar disease. Neuromolecular Med. 1, 111-124.
58. Wessels, J. A., de Vries-Bouwstra, J. K., Heijmans, B. T., Slagboom, P. E., Goekoop-Ruiterman, Y. P., Allaart, C. F., Kerstens, P. J., van Zeben, D., Breedveld, F. C., Dijkmans, B. A., et al. (2006). Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54, 1087-1095.
59. Whiting-O'Keefe, Q. E., Fye, K. H., and Sack, K. D. (1991). Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am. J. Med. 90, 711-716.
60. Whitney, A. R., Diehn, M., Popper, S. J., Alizadeh, A. A., Boldrick, J. C., Relman, D. A., and Brown, P. O. (2003). Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. U.S.A. 100, 1896-1901.
61. Wordsworth, P., and Bell, J. (1991). Polygenic susceptibility in rheumatoid arthritis. Ann. Rheum. Dis. 50, 343-346.
62. Wright, G. W., and Simon, R. M. (2003). A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19, 2448-2455.